Share Twitter LinkedIn Facebook Email Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Read here:Â https://jitc.bmj.com/content/8/1/e000673
Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights AACR 3 Mins Read
Immunotherapy Revolution Unveiled: How TLS-Derived Antibodies Are Changing Cancer Treatment AACR Io 2025 AACR 4 Mins Read
AACR IO 2025: Revolutionary Insights into Desmoplastic Melanoma Treatment – Kari L Kendra, MD, PHD AACR 5 Mins Read
